about
Elimination of the vesicular acetylcholine transporter in the striatum reveals regulation of behaviour by cholinergic-glutamatergic co-transmission.A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients.Quantitative tissue pH measurement during cerebral ischemia using amine and amide concentration-independent detection (AACID) with MRI.Clinical proton MR spectroscopy in central nervous system disordersVitamin D and brain volumetric changes: Systematic review and meta-analysis.In vivo 1H2O T2+ measurement in the human occipital lobe at 4T and 7T by Carr-Purcell MRI: detection of microscopic susceptibility contrast.Quantitative short echo-time 1H LASER-CSI in human brain at 4 T.Effect of signal-to-noise ratio and spectral linewidth on metabolite quantification at 4 T.Enhanced diffusion weighting generated by selective adiabatic pulse trains.Blood pressure levels and brain volume reduction: a systematic review and meta-analysis.A robust and convergent synthesis of dipeptide-DOTAM conjugates as chelators for lanthanide ions: new PARACEST MRI agents.A sensitive PARACEST contrast agent for temperature MRI: Eu3+-DOTAM-glycine (Gly)-phenylalanine (Phe).Analogs of Eu3+ DOTAM-Gly-Phe-OH and Tm3+ DOTAM-Gly-Lys-OH: synthesis and magnetic properties of potential PARACEST MRI contrast agents.Spectroscopic lineshape correction by QUECC: combined QUALITY deconvolution and eddy current correction.T(2) + measurement during acute cerebral ischemia by Carr-Purcell MRI at 4T.Experimental validation of a T2rho transverse relaxation model using LASER and CPMG acquisitions.Comparison of T2 and LASER T2dagger image contrast in a rat model of acute cerebral ischemia.Four-pool modeling of proton exchange processes in biological systems in the presence of MRI-paramagnetic chemical exchange saturation transfer (PARACEST) agents.Endothelin-1 induced MCAO: dose dependency of cerebral blood flow.Optimized MRI contrast for on-resonance proton exchange processes of PARACEST agents in biological systems.In vivo detection of PARACEST agents with relaxation correction.In vivo detection of MRI-PARACEST agents in mouse brain tumors at 9.4 T.A novel MRI-compatible brain ventricle phantom for validation of segmentation and volumetry methods.Reduced hippocampal glutamate in Alzheimer disease.NPAS3 variants in schizophrenia: a neuroimaging study.Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database.Vitamin D and caudal primary motor cortex: a magnetic resonance spectroscopy study.Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.Contribution of brain imaging to the understanding of gait disorders in Alzheimer's disease: a systematic review.Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.MRI and multinuclear MR spectroscopy of 3,200-year-old Egyptian mummy brain.Functional MRI of pain application in youth who engaged in repetitive non-suicidal self-injury vs. psychiatric controls.Real-time display of artifact-free electroencephalography during functional magnetic resonance imaging and magnetic resonance spectroscopy in an animal model of epilepsy.Long component time constant of 23Na T*2 relaxation in healthy human brain.Linear aspects of transformation from interictal epileptic discharges to BOLD fMRI signals in an animal model of occipital epilepsy.Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex.Synthesis of MRI contrast agents derived from DOTAM-Gly-L-Phe-OH incorporating a disulfide bridge: conjugation to a cell penetrating peptide and preparation of a dimeric agent.A paramagnetic chemical exchange-based MRI probe metabolized by cathepsin D: design, synthesis and cellular uptake studies.Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.Motor cortex and gait in mild cognitive impairment: a magnetic resonance spectroscopy and volumetric imaging study.
P50
Q30472919-5EE83FAA-3856-4128-BAF5-4850A2994481Q30577998-40E6436F-5B1C-47DE-B979-7A58B6397184Q30748460-D53F61AB-94D4-4AEF-8AB6-C6B2FF158C15Q30764446-BE2FD316-1F70-42CC-97E8-C67EB981BD4BQ30786917-EF30BC16-6066-4994-82FA-80E8441F9902Q30831627-89E420E3-1A38-42F5-9614-67FB49A39F0AQ31056374-70187A98-E0F4-43BD-8806-EB7E3D99AB09Q31089918-6E56F004-0CA2-440F-A22F-A3BEF4823BDFQ31117230-C7FAC562-C4F1-4070-9497-37B6813DFB7AQ31122275-D2C125EF-270B-4FF6-B21D-00DB8E1A2ECDQ31122311-43F13E9C-EE88-4D8F-9496-B2C85FC15538Q31144440-A5BAD2DE-29EA-4E04-956D-242EBF1141A5Q31154470-ABEFA6CB-7EAE-4266-86BE-6ED6D92E9465Q31813811-D132CA76-0C2E-4B47-A844-133F26A16D14Q33226464-F09E1171-D8DF-46CD-B5D0-57A8E67E8290Q33239995-9A97E11C-B796-4370-83DB-FBBB610029B9Q33308809-519999CB-668F-4D31-8926-E2A2530FC16AQ33380285-4C8E17F3-C3BA-405C-8FBC-8EA4E2FAB8A8Q33442483-89C9D63E-69B7-446C-85F0-74A2E5F92F80Q33506667-77F4C02C-AD2B-43D1-98EE-DE5AC6F082AEQ33568731-6087CBC6-20E5-43D3-8641-EB69B5A81856Q33799575-2B5EDB1D-0A58-4050-866D-26955669DD81Q34186813-3115DF15-E427-4963-B985-4A7DC668EFDBQ34985347-2665B582-8EE6-4910-AF84-A760D74CAF15Q35133013-0E4E5F73-57E6-4DC0-9876-1B2EE2D6E920Q37300216-01E5DCB0-A040-4A53-9F95-52A107EFDFB3Q37538703-3FF6BF04-C93A-4167-BB66-ED4EC68E3289Q37693470-485A9C8C-287B-40A4-AADE-8190C12D3BEDQ38038844-B215D8EF-407C-4CB8-A3ED-950D46E2F571Q38190687-8660F26D-EDC4-4E08-9CD5-591C4DC127E2Q39121790-B078A9A2-D1BA-4870-B360-2B6B68656D1CQ39206160-D3323BA1-E395-45E4-A547-775269B5F7A7Q39706475-9DED3EB8-8BBC-4DA1-87E5-7EF1606C2AE5Q40492704-6FFDB367-09D7-4358-8A6F-14DA69B3C3D9Q42171347-5202DC94-D56E-4E4F-A674-B0F6C02530ABQ42444642-53FF98C3-929D-414F-9A02-5857063F0495Q42939172-02021A6A-1CC3-4CDA-BB3C-222266667F0EQ43059027-F7D45487-FFFA-4F0A-8B62-518FEF24C497Q43260715-C0EF3DAA-71ED-46A8-AC2C-A509D790A9BAQ43587665-933C023A-BDA1-4AFB-96C3-C109A39509DD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Robert Bartha
@ast
Robert Bartha
@en
Robert Bartha
@es
Robert Bartha
@nl
Robert Bartha
@sl
type
label
Robert Bartha
@ast
Robert Bartha
@en
Robert Bartha
@es
Robert Bartha
@nl
Robert Bartha
@sl
prefLabel
Robert Bartha
@ast
Robert Bartha
@en
Robert Bartha
@es
Robert Bartha
@nl
Robert Bartha
@sl
P1053
K-3611-2013
P106
P21
P31
P3829
P496
0000-0002-7118-9096